Choose a language and wait for the translated text.
The British drugmaker said it would be the first late-stage trial of an mRNA flu vaccine designed to target two key surface proteins, haemagglutinin and neuraminidase, an approach GSK said could improve protection and reduce transmission.
GSK to advance mRNA flu vaccine to late-stage trial | PharmaVoice
